Skip to main content
. 2010 Feb 26;107(11):5112–5117. doi: 10.1073/pnas.0915141107

Fig. 1.

Fig. 1.

Drug design and protease degradation-resistance assay. (A) Schematic representation of Arg-Pro-Leu (RPL) retro-inversion. (B and C) Mass-spectroscopy analysis (MALDI-TOF) of RPL and D(LPR) pre- and postincubation with pancreatic enzymes. Peaks corresponding to the intact peptides and enzymatic degradation products are color-coded [red, RPL; blue, D(LPR)] and indicated by arrows.